Interpace Biosciences Guides to Higher Preliminary Q3 2026 Revenue
Interpace Biosciences issued a preliminary, unaudited revenue estimate for the third quarter of 2026, projecting $10.1 million to $10.4 million. The midpoint range implies growth of about 11% to 14% from the second quarter of 2026 and 15% to 18% from the third quarter of 2025. The company cautioned that the figures are not final and remain subject to closing procedures and review by its independent registered public accounting firm.
Interpace Biosciences, a Parsippany, New Jersey-based company trading under IDXG, said its early, unaudited revenue for the quarter ended September 30, 2026, should land between $10.1 million and $10.4 million. The midpoint of that range points to roughly 11%–14% growth from Q2 2026 and 15%–18% growth from Q3 2025.
Management based the estimate on currently available information. The figures still face quarter-end closing work and review by its outside registered accounting firm, so actual results may differ materially. Full Q3 2026 financial results are expected later.
The revenue update could shape investor confidence in Interpace Biosciences, affecting shareholders and possibly the company's access to capital. That, in turn, may influence hiring, supplier relationships, or customer service, though the preliminary nature of the figures limits any immediate real-world effect. Final reported results would provide a clearer basis for such impacts.